A peer-reviewed review of Health Ministry data found active licences and prescriptions fell 7.5% from 140,483 in January 2024 to 129,900 in March 2025, the first decline since 2011. Average approved dose was 40 g/month; flower was 94% of approved products; chronic pain was 63% and PTSD 17% of licences.[1][2]
Listed for context. No score change is recorded for Israel here.
References
- Aviram — Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011–2025Patient numbers, indications, doses and product mix.archived
- JPost — Israeli medical cannabis use falls as HMOs tighten approvals (15 November 2025)archived
Checked. The date and the event were compared with a source that was read.